The new report, “CHINA INSULIN LISPRO MARKET, 2010-2019” provides key data, information and analysis on the China Insulin Lispro Market. The report provides market landscape, competitive landscape and market trends information on the China’s market. Report includes comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics.
There are about 90 million diabetes patients in today’s China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million. For patients with type 1 diabetes mellitus, insulin is the only drug available. Besides, 30%-40% of type 2 diabetes will finally become insulin- dependent. Currently, diabetic drug market at home and abroad both show rapid growth. Although international giants take up a large share, domestic enterprises are expected to break through in certain fields. The vast number of patients and demand for treatment will drive the diabetic drug market to expand. In recent years, insulin’s share in diabetic drug market has increasingly risen, 42% in the global market while nearly 40% in China.
Complete Report Spread across 60 pages with 11 Charts Now Available.
Get Complete TOC of China Insulin Lispro Market, 2010-2019 Research Report at: http://www.marketreportsworld.com/investigation-report-on-china-insulin-lispro-market-2010-2019-10173312
Insulin lispro is a fast-acting insulin analogue. Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, avoiding episodes of hypoglycemia. In the late 1990s, insulin lispro made by Eli Lilly and Company entered China. Later insulin lispro made by Gan & Lee Pharmaceuticals also came into the market.
Access Sample Research Report of China Insulin Lispro Market, 2010-2019 at: http://www.marketreportsworld.com/enquiry/request-sample/10173312
After entering China, insulin lispro develops fast with annual sales rising from less than CNY 7 million in 2005 to CNY 142 million in 2014 and CAGR during 2005-2014 reaching up to 40.1%. Currently, insulin lispro in the Chinese market mainly come from Eli Lilly and Company and Gan & Lee Pharmaceuticals. According to CRI’s market survey, Eli Lilly and Company has larger market share of over 99% in 2014 by sales value.
Request Discount on China Insulin Lispro Market Research Report at: http://www.marketreportsworld.com/enquiry/request-discount/10173312
Key players in Investigation Report on China Insulin Lispro Market, 2010-2019:
Eli Lilly and Company; Gan & Lee Pharmaceuticals
Through this report, the readers can acquire the following information:
-Market size of insulin lispro in China
-Market share of manufacturers of Insulin Lispro in China
-Retail price of insulin lispro in Chinese market
-Major manufacturers of insulin lispro in Chinese market
-Market outlook of insulin lispro in China
Purchase the China Insulin Lispro Market Research Report at: http://www.marketreportsworld.com/purchase/10173312
The author suggests the following groups of people purchase this report:
-Manufacturers of antidiabetic drugs
-Investors/ research institutions interested in Chinese medicine market
This report also provides an analysis of key competition, forecast over next 5 years, anticipated growth rates and the principal factors driving and impacting growth.
- Investigation Report on China Insulin Detemir Market, 2010-2019: http://www.marketreportsworld.com/investigation-report-on-china-insulin-detemir-market-2010-2019-10173306
Market Reports World
Market Reports World is the credible source for gaining the market research reports which will supplement your business with a boost of intelligence. We are among the leading report resellers in the business domain committed towards providing you astute data on market dynamics. A research concocted after assessing current market trends, competition, technological and economic developments is offered to the buyers in the reports we resell. Market Reports World aspire to bestow exhaustive market overview and segmentation which is of a great tactical value for the participants who wish to expedite their growth rate and gain a stronghold in the industry.
P: +1-408 520 9750